WCN26-3246 LONG-TERM EFFICACY AND SAFETY OF BELIMUMAB ON SYSTEMIC LUPUS ERYTHEMATOSUS IN CHILDREN: A META-ANALYSIS OF REAL-WORLD DATA

Read full text Summarise with VIRAT
Authors: Thỵ Phương Anh Lê, El‐Wui Loh, Ka‐Wai Tam
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Belimumab is the first biologic approved for children over five years with systemic lupus erythematosus (SLE), but evidence on its long-term efficacy and safety in pediatric populations remains limited. Therefore, we conducted a systematic review and meta-analysis of real-world data to evaluate the long-term outcomes of belimumab in pediatric SLE, with a specific focus on lupus nephritis (LN), and to compare its potential benefits and risks with standard immunotherapy, aiming to provide comprehensive evidence to guide clinical practice.

Fields of Study & Subjects

Systemic Lupus Erythematosus Research Renal Transplantation Outcomes and Treatments Renal Diseases and Glomerulopathies

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106192–106192
Publication date
25 March 2026
Language
EN